Losartan Potassium Tablet, Film Coated
Product Images NDC 68084-346

14 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68084-346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ahp34601

Ahp34601
Losartan Potassium film-coated tablets shown in white, oblong shape with embossed numbers '2' on one tablet and '7' on the other. The image includes measurement scales in millimeters for size reference. Strength and other product details are not visible on the tablets themselves.*
FDA Label Image

Ahp34701

Ahp34701
Losartan Potassium 100 mg film-coated tablet, oval and white. One side is imprinted with 'Z16', and the other side has a scored line for splitting. This oral tablet is manufactured by American Health Packaging.*
FDA Label Image

Ahp34801

Ahp34801
Losartan Potassium 100 mg film-coated oral tablet. The tablet is white, oval-shaped with an imprinted code 'Z 18' on one side and no markings on the other. Measurement scale indicates the tablet is approximately 12 mm in length. The product is labeled by American Health Packaging.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of the active ingredient Losartan Potassium, showing its molecular framework including a chlorinated ring, a hydroxymethyl group, and potassium ion association.*
FDA Label Image

Figure 1: Kaplan-meier Estimates Of The Primary Endpoint Of Time To Cardiovascular Death, Nonfatal Stroke, Or Nonfatal Myocardial Infarction In The Groups Treated With Losartan Potassium And Atenolol. (Figure1)

Figure 1: Kaplan-meier Estimates Of The Primary Endpoint Of Time To Cardiovascular Death, Nonfatal Stroke, Or Nonfatal Myocardial Infarction In The Groups Treated With Losartan Potassium And Atenolol. (Figure1)
A line graph comparing the percentage of patients with the primary endpoint over study months for Atenolol and Losartan Potassium. Atenolol is represented by a dashed line and Losartan Potassium by a solid line, showing cumulative patient outcomes up to 66 months with an adjusted risk reduction of 13%, p=0.021 indicated.*
FDA Label Image

Figure 2: Kaplan-meier Estimates Of The Time To Fatal/nonfatal Stroke In The Groups Treated With Losartan Potassium And Atenolol. (Figure2)

Figure 2: Kaplan-meier Estimates Of The Time To Fatal/nonfatal Stroke In The Groups Treated With Losartan Potassium And Atenolol. (Figure2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between Losartan Potassium and Atenolol. The y-axis represents the percentage of patients, ranging from 0 to 8%, and the x-axis represents study duration in months. The graph shows lower stroke incidence in the Losartan Potassium group compared to Atenolol, with an adjusted risk reduction of 25% (p=0.001).*
FDA Label Image

Figure 3: Primary Endpoint Events† Within Demographic Subgroups (Figure 3)

Figure 3: Primary Endpoint Events† Within Demographic Subgroups (Figure 3)
A forest plot chart comparing the hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol across patient subgroups. The chart presents event rates for primary composite outcomes and stroke (fatal/non-fatal) categories, subdivided by age, gender, race, ISH status, diabetes, and history of cardiovascular disease. The x-axis shows hazard ratios favoring either Losartan or Atenolol.*
FDA Label Image

Figure 4: Kaplan-meier Curve For The Primary Composite Endpoint Of Doubling Of Serum Creatinine, End Stage Renal Disease (need For Dialysis Or Transplantation) Or Death. (Figure4)

Figure 4: Kaplan-meier Curve For The Primary Composite Endpoint Of Doubling Of Serum Creatinine, End Stage Renal Disease (need For Dialysis Or Transplantation) Or Death. (Figure4)
A line graph depicting the percentage of patients with an event over 48 months comparing Losartan Potassium Tablet and Placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022, with the Losartan Potassium Tablet group having a lower event rate than the placebo group over time.*
FDA Label Image

25 mg Losartan Potassium Tablets Carton (25 mg Losartan Potassium Tablets Carton)

25 mg Losartan Potassium Tablets Carton (25 mg Losartan Potassium Tablets Carton)
Losartan Potassium 25 mg film-coated tablets label for a 100-count package (10 blister packs of 10 tablets) by American Health Packaging. Includes the NDC number 68084-346-01 and instructions for storage, prescription use, and protection of the blister. The label features a barcode and a QR code for current prescribing information.*
FDA Label Image

25mg Losartan Potassium Tablets Blister (25mg Losartan Potassium Blister)

25mg Losartan Potassium Tablets Blister (25mg Losartan Potassium Blister)
Losartan Potassium 25 mg film-coated tablet labels from American Health Packaging. Each label includes the drug name, strength (25 mg), dosage form (film-coated tablet), a barcode, National Drug Code (NDC) number (0036808436118), and space for expiry date and lot number. The manufacturer address is listed as Columbus, Ohio.*
FDA Label Image

50 mg Losartan Potassium Tablets Carton (50 mg Losartan Potassium Tablets Carton)

50 mg Losartan Potassium Tablets Carton (50 mg Losartan Potassium Tablets Carton)
Losartan Potassium 50 mg film-coated tablets label from American Health Packaging. The label shows packaging for 100 tablets (10 x 10) with the National Drug Code (NDC) 68084-347-01. It includes instructions for storage, a QR code for prescribing information, and notes it is Rx only.*
FDA Label Image

50mg Losartan Potassium Tablets Blister (50mg Losartan Potassium Blister)

50mg Losartan Potassium Tablets Blister (50mg Losartan Potassium Blister)
Multiple identical labels for Losartan Potassium 50 mg film-coated tablets, USP. Each label features the product name, strength, form, a barcode, serial, lot, and expiration date placeholders, and the labeler American Health Packaging, Columbus, Ohio. The layout is consistent across all labels shown.*
FDA Label Image

100 mg Losartan Potassium Tablets Carton (100 mg Losartan Potassium Tablets Carton)

100 mg Losartan Potassium Tablets Carton (100 mg Losartan Potassium Tablets Carton)
Losartan Potassium 100 mg film-coated tablets label showing a 100-count package (10 x 10 tablets) for human prescription drug use. The label includes the NDC code 68084-348-01, instructions to see full prescribing information, storage directions at controlled room temperature, and protection warnings. Distributed by American Health Packaging, Columbus, Ohio.*
FDA Label Image

100mg Losartan Potassium Tablets Blister (100mg Losartan Potassium Blister)

100mg Losartan Potassium Tablets Blister (100mg Losartan Potassium Blister)
Multiple identical barcode labels for Losartan Potassium Tablet, USP 100 mg, film coated, oral tablet dosage form. Each label includes a barcode, space for expiration date and lot number, and the American Health Packaging labeler information located in Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.